Search - tctmd.com

Displaying 21 - 40 of 41

Sort: Relevancy | Date

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Daily News

Diabetes Does Not Appear to Hinder FFR Insights for CAD

Caitlin E. Cox

January 09, 2020

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Analysis Supports Aiming for Lower BP in Patients With Diabetes, Hypertension

Todd Neale

April 29, 2019

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Caitlin E. Cox

November 21, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Dapagliflozin Boosts Health Status Across LVEF Range

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Diabetes Does Not Appear to Hinder FFR Insights for CAD

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Analysis Supports Aiming for Lower BP in Patients With Diabetes, Hypertension

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content